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Introduction
Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in metabolic transformation of xenobiotics. It is mainly expressed in intestine and cardiovascular systems including endothelium and myocardiocytes with however low expression level in the liver (Node et al., 1996; Wu et al., 1996; Delozier et al., 2007; Xu et al., 2011) .
Endogenously, CYP2J2 is the epoxygenase that oxidizes arachidonic acid (AA) to regioisomeric cis-epoxyeicosatrienoic acids (EETs), an important class of bioactive eicosanoids (Oliw, 1994; Capdevila et al., 2000; Brash, 2010; Guengerich and Rendic, 2010 ) that exhibits a wide range of cardiovascular protective effects (Baron et al., 1997; Imig et al., 1999; Fleming, 2004; Seubert et al., 2004; Larsen et al., 2006; Xiao et al., 2010) . In recent years CYP2J2 and its EET metabolites have also been implicated in the pathological development of human cancers for both solid tumors and hematological malignancies (Jiang et al., 2005; Freedman et al., 2007; Jiang et al., 2007; Chen et al., 2009; Chen et al., 2011) .
On the other hand, the role that CYP2J2 plays in drug metabolism is not yet fully understood. Previous studies have identified a number of drugs from different disease areas that can be metabolized by CYP2J2, including astemizole, ebastine, terfenadine and vorapaxar (Matsumoto and Yamazoe, 2001; Matsumoto et al., 2002; Liu et al., 2006; Lee et al., 2012) . More importantly, it is indicated that CYP2J2 plays a dominant role in the first-pass intestinal metabolism of ebastine to its pharmacologically active metabolite carebastine (Hashizume et al., 2002; Matsumoto et al., 2002; Lee et al., 2010) . In a recent publication a number of structurally diverse substrates of CYP2J2 have been identified ranging from albendazole with a molecular weight of only 265 to complex molecules such as cyclosporine with a molecular weight of 1201 (Lee et al., 2012) . With DMD #048264 its rather broad substrate spectrum and unique tissue distribution pattern, it is possible that CYP2J2 can influence drug metabolism in the extrahepatic tissues, particularly the intestine, which may therefore dominate first-pass metabolism for certain drugs and cause drug-drug interaction (DDI) in the gastrointestinal tract. Indeed, the latest guidance for industry on drug interaction studies from the U.S. Food and Drug Administration (FDA) suggests that CYP2J2 should be considered if a new drug candidate is found to be not metabolized by the major CYPs, indicating the increasingly more recognized role of CYP2J2 in drug metabolism (US Department of Health and Human Services, 2012) .
In order to fully characterize CYP2J2 in drug metabolism both in vitro and in vivo, the specific metabolic reactions mediated by CYP2J2 and the potent and selective inhibitors against this CYP isoform are indispensible tools. Using recombinant CYP2J2 enzyme, screening of substrate and inhibitor of this CYP isoform can be performed, as specific substrate can be useful for profiling CYP2J2 inhibition of drug candidates in vitro in liver microsome using cocktail method while specific potent CYP2J2 inhibitor can also facilitate the evaluation of the role that CYP2J2 plays in liver microsomal metabolism and DDI in vivo. Several metabolic reactions have been reported to date to be primarily mediated by CYP2J2, which include astemizole O-demethylation, ebastine hydroxylation, and recently identified amiodarone 4-hydroxylation (Matsumoto et al., 2002; Liu et al., 2006; Lee et al., 2012) . These specific reactions can be useful tools to determine CYP2J2 activity and its roles in drug metabolism. Moreover, the specific tool inhibitor preferably shall not be the substrate of CYP2J2, as it would otherwise add unnecessary complexity in both experimental design and data analysis. Unfortunately, only very few marketed drugs are found to be non-CYP2J2 substrate, but exhibiting potent and selective CYP2J2 inhibition. In one study, Lafite et al. reported a tool DMD #048264 6 compound derived from terfenadine as potent CYP2J2 inhibitor without knowing however its selectivity against several major CYPs including CYP2D6 and CYP1A2 (Lafite et al., 2007) . Very recently Lee et al. screened a library of 138 marketed drugs and showed 42 of them had CYP2J2 inhibitory activity greater than 50% at a single compound concentration of 30 μ M (Lee et al., 2012) . Among them danazol was shown to be a potent CYP2J2 inhibitor with a K i value of 20 nM, albeit that it also inhibits other key CYPs such as CYP2C9 and CYP2D6 with IC50 values at single digit μ M range. It is noted that all of them are CYP2J2 substrates and mechanistically characterized as competitive CYP2J2 inhibitor (Lafite et al., 2007; Lee et al., 2012) . Given the increasingly important role CYP2J2 plays in drug metabolism and first-pass intestinal metabolism in particular, it is essential to expand our repertoire of tool drugs with potent and selective CYP2J2 inhibition, preferably a non-substrate compound, to facilitate the study for CYP2J2-mediated drug metabolism and clinically relevant drug-drug interaction potential.
In the current study, we selected 69 known drugs and tested their inhibitory activity against astemizole O-demethylation, a well-known reaction catalyzed by CYP2J2. Among them, 12 compounds were showed to have an IC50 value less than 10 μ M. Specifically, telmisartan, flunarizine, norfloxacin and metoprolol were found to be selective inhibitors against CYP2J2 in the sub-μM range. Both telmisartan and flunarizine were also demonstrated to be the non-substrate inhibitors of CYP2J2.
Telmisartan also exhibits a mixed type inhibition mechanism while flunarizine shows a competitive inhibition, consistent with the computer modeling studies at a molecular and thermodynamic level. In conclusion, a number of currently marketed drugs have been discovered as CYP2J2 inhibitors that can be potentially used as new tools to study the This article has not been copyedited and formatted. The final version may differ from this version. parameter logistic model) were used for activity and inhibition calculations, respectively.
A combination of both graphical and statistical approaches was used to determine the most suitable inhibition model, i.e., competitive, non-competitive, mixed, or uncompetitive. Specifically, the Dixon plots were used as the graphical method and more importantly the non-linear regression analysis played a dominant role in determining the type of inhibition. The statistical parameters from the non-linear regression analysis were obtained using GraphPad Prism 5.01 (GraphPad Software, Inc., La Jolla, CA, USA), which include R 2 value, standard deviation of the residuals (Sy.x), and a sum-of-squares F-test. Specifically, for simple models, it was determined by the best R 2 and the smallest
Sy.x values, while for complex model, the F-test was used to test whether or not a complex model (with added parameters) would be a better fit. When a p-value smaller than 0.05 is observed, the complex model is accepted, otherwise the simple model will be accepted. The estimated K i was then determined based on the selected inhibition model.
The following equations were used to determine the K i value for each model, respectively:
Competitive:
Non-competitive:
Linear mixed:
Uncompetitive:
This article has not been copyedited and formatted. The final version may differ from this version. (Li et al., 2008) was used for the docking study. The protein was prepared by the Protein Preparation Wizard module in the Schrödinger suite of programs and the ligands were prepared by the LigPrep module. All docking studies were carried out using the Glide module Halgren et al., 2004) and both the Glide docking score and visual inspection were applied to select the most suitable poses for subsequent dynamics simulation.
Regarding the initial structure, the entire system contains three parts: the protein, heme, and ligand. The parameters for the protein were from the force field 99SB (FF99SB) in the AMBER11 package (Case et al., 2005) . D. Giammnona provided the heme parameter (Giammona, 1984) in the AMBER11 package. As for the ligand, we used the following standard procedure to prepare the parameters. First, we minimized the ligands with Gaussian 09 at the HF/6-31G* level (Frisch et al., 2009 ). The minimized structure was then used to calculate the single-point electrostatic potential at HG/6-31G* level. Using the resultant electrostatic potential, we applied the RESP (Bayly et al., 1993) model in AMBER11 to fit the partial charges of the ligand. The generalized AMBER force field (GAFF) parameters (Wang et al., 2004) were then applied for the ligand. The whole system was solvated in a periodic box of TIP3P waters (Jorgensen et al., 1983) , and the minimum distance from the surface atom to the edge of the box was set to 12 Å. Counterions were also added to neutralize the entire system. This article has not been copyedited and formatted. The final version may differ from this version. The molecular dynamics (MD) simulations were carried out using the AMBER11 package. The cutoff for the long range interaction was set at 10 Å and the particle mesh Ewald (PME) method (Darden et al., 1993) was applied to treat the long range electrostatic interaction. The SHAKE algorithm (Miyamoto and Kollman, 1992) was applied to restrain all bonds involving the hydrogen atoms. The simulations followed the same protocol. First, all the water molecules, counterions, and hydrogen atoms were minimized for 20000 steps by the steepest descent approach followed by 30000 steps of conjugate gradient minimization with rest the system fixed. The whole system was further minimized using conjugate gradient to convergence with a criteria of 10
kcal/mol/Å of the root-mean-square of the Cartesian elements of the gradient. The system was then gradually heated from 0 to 300 K for 100 ps with a 10.0 kcal/mol/Å 2 restraining force applied on the protein-ligand complex. The Langevin dynamics temperature coupling scheme was applied (Pastor et al., 1998 ) and the collision frequency was set at 2.0 ps -1 . Finally, we completely relaxed the whole system and ran the production simulation for 2 ns using the NPT ensemble with a time step of 2 fs.
Binding Free Energy Calculation.
A total of 100 snapshots were extracted at 2 ps interval from the last 200 ps simulation for the binding free energy calculation. The protein together with the heme was defined as the receptor. The molecular mechanics generalized Born surface area (MM-GBSA) method (Qiu et al., 1997) was applied to compute the binding free energy between the ligand and the receptor. The total binding energy can be expressed as: (Bondi, 1964) were used for all atoms. It is noteworthy that we set the F atom radius to 1.47 Å (Batsanov, 2001) , which is not included in the standard AMBER11 package. The nonpolar contribution (ΔG nonpolar ) is calculated using the LCPO method (Weiser et al., 1999) and can be expressed as:
The SASA is the solvent-accessible surface area obtained from the MOLSURF program (Connolly, 1983) and the SURFTEN and SURFOFF parameters were 0.0072 and 0, respectively. The radius of probe sphere was set 1.4 Å. The entropic contribution (TΔS)
to the binding free energy was not considered in our calculation.
Results
This article has not been copyedited and formatted. The final version may differ from this version. characterize the metabolic/enzymatic activity of CYP2J2 as this biotransformation is well known to be catalyzed primarily by CYP2J2 in human (Matsumoto et al., 2002; Lee et al., 2012) . The metabolizing activity of CYP2J2 for astemizole O-demethylation was measured to ensure that substrate concentration used in the follow-up inhibition studies was suitably around the K m value. Under our experimental conditions, the apparent kinetic parameters of astemizole O-demethylation using recombinant human CYP2J2
were determined as the followings: K m = 0.09 ± 0.01 μ M and V max = 339 ± 13.0 pmol/min/nmol protein (n = 2).
Telmisartan and Flunarizine Show Significant and Selective Inhibition against CYP2J2.
A total of 69 marketed drugs were screened by using this in vitro astemizole O-demethylation system to characterize their inhibitory effect on CYP2J2 activity. The results are shown in Table 3 In order to evaluate the selectivity of CYP2J2 inhibition and given its predominant expression in the extrahepatic tissues such as intestine, we examined the inhibitory effect of these 20 compounds against five major human CYP isoforms including CYP3A4, CYP2C9, CYP2C19, and CYP2D6 which are also the most abundantly expressed CYP isoforms in the human intestine (Ding and Kaminsky, 2003;  This article has not been copyedited and formatted. The final version may differ from this version. Paine et al., 2006) and CYP1A2. As shown in Table 3 , besides inhibition of CYP2J2 telmisartan also inhibits CYP2C9 (IC50 = 4.8 μ M), nearly 10-fold less potent comparing to that of CYP2J2. On the other hand, telmisartan does not exhibit any inhibition against other four major CYPs including CYP3A4 and CYP2D6. Similarly, flunarizine only inhibits CYP2D6 with an IC50 of 7.8 μ M, which is also about 10-fold less potent than that of CYP2J2, and shows minimum inhibition for other four key CYPs (IC50 > 50 µM).
Moreover, amodiaquine is a potent inhibitor for both CYP2J2 (IC50 = 0.99 μ M) and CYP2D6 (IC50 = 0.64 μ M). In addition, it is noteworthy that both norfloxacin and metoprolol display excellent selectivity for CYP2J2 with IC50 values of 2.6 and 4.9 μ M, respectively and are not active against all five major CYPs (IC50s > 50 μ M; Table 3 ). plot does not go through the origin) while flunarizine is a competitive inhibitor (i.e., the plot goes through the origin). We then applied the non-linear regression analysis to further confirm the inhibition type of both drugs. When simple models were used, flunarizine inhibition kinetics was best fitted to a competitive model. Subsequently, when we tried to use a more complex mixed model to fit the data, we obtained a p-value of 0.78, much greater than the threshold 0.05, indicating that flunarizine is indeed a competitive inhibitor of CYP2J2 with a K i value of 0.13 ± 0.02 μ M. The data of telmisartan inhibition kinetics could be fitted by a non-competitive model. However, those data could be even better fitted by a more complex mixed model, and the p-value was 0.039. Based on these model fitting results it was suggested that the inhibition mechanism of telmisartan could be described by a linear mixed type inhibition model.
Telmisartan and Flunarizine
The corresponding K i of telmisartan is 0.19 ± 0.05 μ M with an α value of 2.80 ± 1.39. In overall, these data indicate that flunarizine likely inhibits CYP2J2 enzymatic activity by directly competing with the substrate (in this case astemizole), whereas telmisartan might inhibit the enzyme in an allosteric fashion.
Computer Modeling Studies of the CYP2J2 Inhibition Mechanism by
Telmisartan and Flunarizine. In order to further delineate the distinctive inhibition mechanisms of telmisartan and flunarizine as indicated by the inhibition kinetics studies, we set out to apply computational modeling approaches to study the interactions between the inhibitor and CYP2J2 on a molecular level. The CYP2J2 model was previously described by Li and colleagues (Li et al., 2008) and was used as the starting structure in the study. The docking models of the telmisartan-CYP2J2 and flunarizine-CYP2J2 complexes are shown in Figure 5 , panels A and B, respectively. Interestingly, telmisartan and flunarizine seem to occupy different regions of the CYP2J2 ligand binding pocket. We further subjected the two complex systems to all-atom molecular dynamics simulation. The CYP2J2 protein displays limited overall conformational change in both systems, while the inhibitor telmisartan exhibits greater conformational flexibility than flunarizine within the CYP2J2 binding pockets ( Figure 5 , panels C and D).
As shown in Figure 6 , telmisartan binds to a pocket that is remote to the catalytically important heme with a minimum distance between telmisartan and heme of To further study how telmisartan and flunarizine interact with CYP2J2 from a thermodynamics point of view, we carried out MM-GBSA calculation to estimate the inhibitor binding free energy to CYP2J2 ( (Table 4) . Moreover, although both telmisartan and flunarizine make one hydrogen bond to the protein, namely Arg484 side chain and Ile487 backbone, respectively, the polar and/or electrostatic interaction between both ligands and the protein is minimum. This is reflected in the unfavorable electrostatic binding free energy in both cases (Table 4) inhibitors can be useful tools for studying CYP2J2-mediated drug metabolism and CYP2J2 biological functions.
Anti-hypertension Drugs Telmisartan and Flunarizine Can Be Used to Study
CYP2J2-related DDI in a Clinical Setting. Drug-drug interaction can be caused due to inhibition by one drug on a particular CYP isoform that is responsible for metabolism of another molecule at both the hepatic and intestinal levels. This may cause significantly changed pharmacokinetics of the second drug which might lead to unwanted adverse effects. Therefore, knowledge on potent inhibitors of specific CYP isoforms, especially those involved in xenobiotics metabolism, is critical for the clinical use of those medicines, and is important for the discovery and development of drugs metabolized by those specific CYP isoforms. Besides at a systematic level where liver is the major organ responsible for metabolic DDI, the gastrointestinal (GI) tract is also where DDI commonly takes place mainly due to the existence of high level metabolic enzymes and high free concentration of drugs when administered orally. Though no DDIs involving CYP2J2 have been reported in the clinic so far, it is possible that CYP2J2 could be an important CYP isoform for drug interactions in the future, especially at the GI level, given its predominant expression in the small intestine and its rather broad, and growing, substrate spectrum.
In this study two marketed drugs telmisartan and flunarizine are shown to be the most potent CYP2J2 inhibitors with low μ M Ki values. Both telmisartan and flunarizine are commonly prescribed anti-hypertension drugs for chronic use with good tolerability and safety profiles as reported in several human studies, where telmisartan and flunarizine were dosed as high as 160 mg and 10 mg, respectively, once daily (Van Hecken et al., 1992; Stangier et al., 2000) . In the case for telmisartan, at steady state the plasma maximum concentration (C max ) can be as high as 3 μ M (1500 ng/mL), 15-fold higher than its K i value, 0.19 Young et al., 2000) . Notably, in the GI tract the concentration could be even much higher. Therefore, it is conceivable that telmisartan may have CYP2J2 inhibitory effects at both intestinal and systemic levels. In the case of flunarizine albeit relatively low plasma concentration from 0.1 to 0.3 μ M given 10 mg daily dose, its intestinal concentration could still be as high as several μ M (Bialer, 1993) , comparing to its 0.13 μ M K i value against CYP2J2. Furthermore, the absorption of flunarizine is relatively slow with T max of 4 hours in human (Bialer, 1993) , which indicates that the high concentration of flunarizine in the GI tract could be maintained to have a lasting inhibitory effect of CYP2J2.
Interestingly, it has been shown that telmisartan can increase the exposure of nisoldipine, a dihydropyridine calcium channel blocker, in patients with essential hypertension (Deppe et al., 2010) . The mechanism for this observed drug interaction remains unclear as nisoldipine is primarily metabolized by CYP3A4 and telmisartan has no significant inhibitory effects to this CYP. Indeed, previously telmisartan was not expected to be involved in any CYP-mediated drug interactions. However, in this case the increased exposure of nisoldipine by co-administrated telmisartan could be related to CYP2J2 inhibition. It is noted nonetheless that interaction between telmisartan and the ATP-binding cassette (ABC) transporters could also contribute to the observed DDI . The most recent FDA guidance for industry on drug interaction studies also suggests to include CYP2J2 when a new drug candidate is found to be not metabolized by the major CYPs (US Department of Health and Human Services, 2012).
Under the circumstances, attention should be paid on the DDI potentials for both telmisartan and flunarizine with future co-administered compounds when the metabolism and elimination of these compounds are mainly mediated by CYP2J2. Also, both telmisartan and flunarizine can be potentially used as tool drugs to assess clinically relevant metabolic DDI related to CYP2J2.
Telmisartan and Flunarizine Are the First Discovered Non-substrate
Inhibitor for CYP2J2. Ideally, the inhibitor that is used as a tool to study a CYP isoform should not be the substrate of that specific CYP enzyme; otherwise, to the least it would add complexity in experimental design. For example, one has to be very careful during the course of the experiment to ensure that the reaction time is short enough so that the degradation of such inhibitor due to metabolism is less than 20%. On the other hand, this often limits the formation of the metabolite to the extent that it is difficult to be detected by routine LC/MS equipment and therefore restricts the application of such inhibitors. In the case of CYP2J2, all the previously known potent inhibitors are also CYP2J2 substrates (Lafite et al., 2007; Lee et al., 2012) . Inspired by the structural model that telmisartan binds to a pocket that is distant to the CYP2J2 catalytic center and may inhibit CYP2J2 by blocking substrate entrance and/or product egress (Figure 8 , panel A),
we hypothesized that telmisartan might not be a substrate to CYP2J2. This was This article has not been copyedited and formatted. The final version may differ from this version. subsequently confirmed by the experimental data that telmisartan is not metabolized after being incubated with the recombinant CYP2J2 for 30 minutes (Figure 2) . Similarly, we subjected flunarizine to the same experimental procedure and determined that it is also not a substrate of CYP2J2 (Figure 2) . It is therefore for the first time that the newly discovered potent and selective CYP2J2 inhibitors are not a substrate of the enzyme. In addition, as shown above in HLM telmisartan is nearly completely not metabolized and flunarizine is only marginally metabolized; these findings are in line with the literature reports (Bialer, 1993; Deppe et al., 2010) . Therefore, using these non-substrate CYP2J2
inhibitors that are also metabolically stable in human liver microsome, both telmisartan and flunarizine can be invaluable tools for studying CYP2J2 in drug metabolism and disposition in different experimental settings.
In order to evaluate the participation of CYP2J2 in drug metabolism in human liver microsome using telmisartan and/or flunarizine, it is important to identify a suitable concentration for both compounds that is able to achieve sufficient CYP2J2 inhibition while at the same time generates limited inhibition toward other major metabolizing CYPs. Given their K i values, namely 0.19 μ M for telmisartan and 0.13 μ M for flunarizine, and their selectivity profiles (Table 3) , it is therefore suggested that a concentration range of 1 to 2 μ M for telmisartan and 0. astemizole, where it makes interactions with both the heme moiety and residues on the long helix I that are close to the catalytic center. Furthermore, the F atom on flunarizine is very close to the heme catalytic Fe atom (the distance is 3.3 Å) and in the same location where the astemizole methoxy group is, which is known to undergo demethylation metabolism catalyzed by CYP2J2. This structural model is consistent with the fact that flunarizine is not a substrate of CYP2J2 as the F atom that is close to the heme is generally metabolically inert. In fact, introducing F atoms into a small molecule is a well-known strategy in lead optimization to improve metabolic stability. Therefore, it is plausible that flunarizine not only competes the substrate at the binding site with astemizole but also at the catalytic center for reaction.
On the other hand, telmisartan binds to CYP2J2 in a grossly different fashion compared to flunarizine. Though both drugs have interactions with a limited number of overlapping CYP2J2 residues, primarily those from N-terminal loop and helix A, sheet β4 and associate loop, as well as K/β1-4 segment, there are significant differences.
Specifically, telmisartan has extensive interactions with the F/G segment, particularly helix F', but is nowhere near the catalytic heme and helix I; on the contrary, as discussed above flunarizine is in close contact with both heme and helix I but has no interactions with the F/G segment ( Figure 8, panel A) . It has been widely suggested that the F/G segment and the B/C segment in mammalian cytochrome P450s are the most flexible parts and likely constitute the gates for substrate entrance and/or product egress paths that are necessary to gain access to the active site heme (Otyepka et al., 2007) . Given that and the binding mode of telmisartan, we suggest that telmisartan might inhibit CYP2J2
This article has not been copyedited and formatted. The final version may differ from this version. protein are also observed (Figure 8 ). Those structural observations corroborate well with the kinetics data that telmisartan is an allosteric inhibitor of CYP2J2 enzyme.
In conclusion, in this report we have discovered for the first time a number of marketed drugs, including telmisartan and flunarizine, as potent, selective, and nonsubstrate CYP2J2 inhibitor. Our enzyme kinetics and computer modeling studies have also elucidated their inhibition mechanisms on a molecular level that telmisartan is an allosteric CYP2J2 inhibitor while flunarizine is a direct substrate competitor. Given our increasing understanding of CYP2J2's role in drug metabolism, these newly discovered inhibitors can be potentially used as tools to study CYP2J2 in drug metabolism, particularly involving drug-drug interaction, and its biological functions.
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